Safety and tolerability of SOR-C13 in patients with advanced solid tumours

Dr. Toney Illenchuk, of Soricimed Biopharma, Inc. in Hamilton is presently investigating the potential of using the drug SOR-C13 as an intravenous infusion in patients with ovarian cancer, "or other cancers known to over express the TRPV6 calcium channel." Thus, both males and females over the age of 18, diagnosed with a solid tumour cancer of epithelial origin, may be suitable candidates for this trial. As Dr. Illenchuk's team points out, ideal candidates for the study are patients for which "palliative measures do not exist or are no longer effective." More information on the study can be found here.